

In Vitro Systems for the Assessment of Chronic Cardiotoxic Effects: News from the HESI Stem Cell Working Group

M. Gossmann¹, U. Thomas², E. Dragicevic², R. Vaidyanathan³, B. Lickiss¹, O. Filali³, S. Stölzle-Feix², P. Linder¹

¹ innoVITRO GmbH, Artilleriestraße 2, 52428 Jülich, Germany

² Nanion Technologies GmbH, Ganghoferstraße 70a, 80339 München, Germany

³ Fujifilm Cellular Dynamics International, 525 Science Drive, Madison 53711, Wisconsin, USA



Abstract

Since long-term exposure of cancer-related therapeutics have been linked to alterations of cardiac function in patients, the Stem Cell Working Group as part of the Health and Environmental Science Institute (HESI) endeavors to gain further insight into chronic cardiotoxicity. The objective of the study was to optimize non-clinical safety assessment strategies of chronic cardiotoxicity by testing prolonged exposure of reference compounds on cell-based assay systems using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

Study Outline

A panel of 12 compounds was selected to evaluate chronic adverse side effects on hiPSC-CMs, including alterations in energetics and contraction force as well as electrophysiological and structural disturbance.

For the quantification of adverse side effects, a variety of methods was used, covering electrophysiology, mechanobiology, optical methods as well as biochemical assays.

Target Toxicity	Compound	Conc. Range	Parameter	Method
Energetics/ Mitochondrial Toxicity	Doxorubicin	0.1 - 3 µM	Electrophysiology	Multielectrode array
	Erlotinib	0.3 - 10 µM		Impedance
	Sunitib	0.01 - 1 µM		Mechanobiology
Electrophysiological Disturbance	Pentamidine	0.1 - 3 µM	Optical Methods	Optical contraction analysis
	Arsenic Trioxide	0.1 - 3 µM		Voltage sensitive dye
	BMS-986094	0.1 - 3 µM		Calcium imaging
Contractility	Milrinone	0.1 - 10 µM	Biochemical	Oxygen consumption rate
	Nilotinib	0.1 - 10 µM		Biomarkers
	Endothelin-1	0.3 - 100 nM		
Structural/myofibril Disturbance	Vinblastine	1 - 300 nM		
	Vincristine	1 - 300 nM		
	Vinorelbine	0.1 - 3 µM		

↑ Table 2: Methods used for the quantification of chronic cardiotoxic compound effects
 ← Table 1: Cardiotoxic compounds sorted by target toxicity
 green: presented in this poster

Technology

iCell Cardiomyocytes² are highly pure human iPSC-derived cardiomyocytes and allow for robust and reproducible quantification of compound effects as demonstrated in the CiPA study (Blinova et al., 2017).

The CardioExcyte 96 is an impedance-based system where hiPSC-derived cardiomyocytes are cultured on gold electrodes, enabling label-free and continuous quantification of electrical impedance as a measure of monolayer integrity.

In the FLEXcyte 96 system, hiPSC-derived cardiomyocytes are cultured on ultra-thin silicone membranes, mimicking the mechanical environment of native human heart tissue. Rhythmic contractions deflect the membranes, quantified by capacitive distance sensing. Parameters analyzed are contractile force (AMP), beat rate (BR), beat rate regularity (BRR), rising time (RT), falling time (FT). (Gossmann et al., 2016 and 2020).




Figure 1: FLEXcyte 96 contraction analysis parameters

Workflow

hiPSC-CMs were seeded from cryopreserved state into the assay format and cultured in maintenance medium for 5 days. 24h prior to compound application, medium was changed to serum-free, protein-containing assay medium. Baseline measurements were performed before compound application. Compounds were added 4x concentrated during a partial media change. The first compound measurement was carried out after 1h. Subsequently, chronic compound responses were recorded in 24h intervals for a total of 120h.




Figure 2: Study workflow

Results




Figure 3: Contraction parameter analysis at 72h post compound application. Parameters: Contraction force (AMP), Beat rate (BR), Beat rate regularity (BRR), Rising time (RT), Falling time (FT)

Target Toxicity	Compound	C1	C2	C3	C4
Energetics/ Mitochondrial Toxicity	Doxorubicin	0.75	0.45	0.40	0.36
	Erlotinib	0.95	0.99	1.03	1.00
	Sunitib	0.94	1.10	1.23	1.33
Ephys Disturbance	Pentamidine	0.94	0.94	0.81	0.62
Contractility	BMS-986094	0.93	0.78	0.83	0.77
	Nilotinib	0.96	1.09	1.14	1.00
Structural/myofibril Disturbance	Endothelin-1	0.82	0.83	0.86	0.87
	Vincristine	0.90	0.57	0.43	0.46

Table 3: Effect of the tool compounds on the base impedance as a measure of monolayer integrity

- **Doxorubicin** had a strong toxic effect, measured both in contraction force as well as monolayer integrity.
- **Erlotinib** had only slight effects on the BRR of hiPSC-CMs and no effect on monolayer integrity.
- **Sunitinib** had a strong effect on the chronotropy (BR, BRR), but rather low effect on the contractile force. The monolayer integrity was increased.
- **Pentamidine** had a strong effect on the contraction force and on the monolayer integrity.
- **BMS-986094** had a major impact on all contractile parameters and on the monolayer integrity.
- **Nilotinib** had a strong effect on the contractile parameters, while the monolayer integrity remained unchanged.
- **Endothelin-1** had a positive effect on the contraction force, but little or no effect on the monolayer integrity.
- **Vincristine** had minor effects on the contractile parameters, but a major effect on the monolayer integrity.

References:

- Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., Zamora, V., Smith, G., Crumb, W. J., Pang, L., Lyn-Cook, B., Ross, J., Brock, M., Chvatal, S., Millard, D., Galeotti, L., Stockbridge, N., & Strauss, D. G. (2017). Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. *Toxicological sciences: an official journal of the Society of Toxicology*, 155(1), 234–247.
- Gossmann, M., Frotscher, R., Linder, P., Neumann, S., Bayer, R., Epple, M., Staat, M., Artmann, A. T., & Artmann, G. M. (2016). Mechano-Pharmacological Characterization of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells. *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology*, 38(3), 1182–1198.
- Gossmann, M., Linder, P., Thomas, U., Juhasz, K., Lemme, M., George, M., Fertig, N., Dragicevic, E., & Stölzle-Feix, S. (2020). Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment. *Journal of pharmacological and toxicological methods*, 105, 106892.

